Salvatore Thomas Butera - Jun 23, 2022 Form 4 Insider Report for VOLITIONRX LTD (VNRX)

Role: CEO - Volition Veterinary
Signature: /s/ Salvatore Thomas Butera
Stock symbol: VNRX
Transactions as of: Jun 23, 2022
Transactions value $: $0
Form type: 4
Date filed: 6/24/2022, 04:05 PM
Previous filing: Jun 17, 2022
Next filing: Aug 23, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VNRX	Stock Option (Right to Buy)	Award	$0	+34.1K	+185.71%	$0.00	52.4K	Jun 23, 2022	Common Stock	34.1K	$3.40	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On August 3, 2021, the reporting person was granted an option to purchase 52,400 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 34,060 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 17,030 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 18,340 shares subject to the award previously vested and remain subject to time-based vesting.

Content

On August 3, 2021, the reporting person was granted an option to purchase 52,400 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 34,060 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 17,030 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 18,340 shares subject to the award previously vested and remain subject to time-based vesting.